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data covering the period between January 2000 and December 2005. The outcome 
variables captured cost of readmissions for a CVD-related condition following an 
index CVD-related admission. The covariate of interest was an indicator variable for 
a discharge AMA in the index hospitalization. The difference in the cost of readmis-
sions (at 7-, 31-, 180-, and 365- day intervals) following formal discharges and dis-
charges AMA was examined using Heckman sample selection models and log linear 
models. The Heckman sample selection model was found to provide a better repre-
sentation of the data generation process. RESULTS: The sample included 443,049 
patients, of which 24,823 (5.6%) were readmitted to the same hospital. Approxi-
mately 1% of the patients who were readmitted to the hospital during the study period 
left AMA on the index admission while 0.87% of those who were not readmitted left 
AMA (p < 0.001). The cost of the ﬁrst readmission within 180 days was 9% (p = 
0.03) higher for patients discharged AMA on index admission compared to those who 
were discharged formally. The cost of all readmissions within 180 days and 365 days 
were 10% (p = 0.02) and 9% (p = 0.02) higher for patients discharged AMA on index 
admission compared to those who were discharged formally. CONCLUSIONS: A 
self-discharge AMA among patients admitted for CVD is associated with higher 
readmissions costs when readmissions occur within 6 months or 1 year.
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OBJECTIVES: To identify the differences in the number of restenosis after the place-
ment of sirolimus-eluting stent vs. zotarolimus-eluting stent and measure their related 
costs. METHODS: A literature review was conducted to identify meta-analysis or 
randomized clinical trials (RCT) that compared sirolimus-eluting (SES) and zotaroli-
mus-eluting (ZES) stents. The clinical outcome of interest was angiographic restenosis 
after stent placement given that this is a surrogate ending point that may predict late 
mortality. The results of the SORT OUT III trial with 2,333 patients were used which 
demonstrated that SES offered a lower rate of restenosis vs ZES (0.25% vs 1.25%) 
(HR: 4.62; 95 CI, 1.33–16.1, p = 0.02) (Lassen, 2008). The perspective is from a 
private payer in Brazil. Local guidelines for economic evaluation of health care tech-
nologies were followed (Vianna, 2007). A decision model was built in Excel. Resource 
usage was raised in a panel with hospitals and valued by micro-costing based on public 
sources (CBHPM 5th edition, PROAHSA, Brasíndice and SIMPRO). Only direct costs 
were considered and reported in 2010 Brazilian Reais (USD1 = R$1.75). Discount 
rate was not applied given the 1-year horizon of the study. A 500,000 cohort was 
taken for a revascularization incidence of 932/100,000 (Ryen, 2009). A one-way 
sensitivity analyses was performed. RESULTS: Based on our model SES patients had 
fewer cases of restenosis vs ZES (12 vs 58).Total cost for the SES group was 1.87% 
below the one found in the ZES group (R$ 29,008 vs R$ 29,559). CONCLUSIONS: 
Results suggest SES patients had a risk reduction of restenosis compared with ZES 
patients. Besides SES offer a 1.87% potential reduction in costs.
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OBJECTIVES: Clopidogrel’s effectiveness is reduced signiﬁcantly for secondary pre-
vention of thrombotic events after acute coronary syndrome (ACS) in patients with 
CYP2C19*2 mutations. Ticagrelor, a novel antiplatelet agent, does not require activa-
tion by the CYP2C19 enzyme and was superior to clopidogrel in a recent secondary 
prevention trial. In 2011, clopidogrel will lose its patent protection and likely will be 
substantially less expensive than ticagrelor. We aim to determine the cost-effectiveness 
of genotype-driven treatment, in which ticagrelor is prescribed in the presence of 
CYP2C19*2 mutations and clopidogrel in their absence, compared to prescribing 
ticagrelor universally. METHODS: A hybrid decision tree/Markov model was used to 
derive 30-year medical costs (in 2009 US$) and outcomes for a cohort of Medicare 
ACS patients of age 65 receiving either a genotype-driven or ticagrelor-only treatment. 
Outcomes included life years and quality-adjusted life years (QALYs) gained. Data 
comparing the clinical performance of ticagrelor and clopidogrel were derived from 
the PLATO study. Mortality and repeat myocardial infarction risk were estimated 
using Medicare inpatient claims of ACS patients. Costs and quality adjustments were 
derived from literature reviews. RESULTS: Over a 30-year period the incremental 
cost-effectiveness ratio (ICER) for universal ticagrelor was $8,827 per QALY com-
pared to genotype-driven treatment. Universal ticagrelor and genotype-driven treat-
ment had respective per capita costs of $10,096 and $8,868. Universal ticagrelor 
resulted in 0.14 QALYs gained per person relative to genotype-driven treatment. The 
ICER was most sensitive to the price of ticagrelor and the hazard ratio for death for 
ticagrelor compared with clopidogrel and remained below $50,000 per QALY until 
a monthly price of $737 for ticagrelor or a 0.93 hazard ratio for death for ticagrelor 
relative to clopidogrel. In probabilistic analyses, the ICER was below $50,000 per 
QALY in 97.4% of simulations. CONCLUSIONS: Prescribing ticagrelor universally 
increases quality-adjusted life expectancy for ACS patients at a cost below typically 
accepted thresholds.
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BASED ON THE JUPITER STUDY
Talavera J1, Jensen MM2, Anaya P3, Polanco AC3, Gandhi SK4
1Mexican Social Security Institute, D.F., Mexico, 2AstraZeneca, Lund, Sweden, 3AstraZeneca, 
Naucalpan, Mexico, 4AstraZeneca LP, Wilmington, DE, USA
OBJECTIVES: To assess the cost-effectiveness of rosuvastatin 20 mg for prevention of 
major cardiovascular disease (CVD) events and mortality compared with no treatment 
alternative in a higher CVD risk population based on ﬁndings from JUPITER (Justiﬁca-
tion for the Use of statins in Primary prevention: an Intervention Trial Evaluating 
Rosuvastatin). METHODS: A probabilistic Monte Carlo simulation model estimated 
long-term cost-effectiveness of rosuvastatin therapy (20 mg daily) for the prevention of 
CVD mortality and morbidity. Using outcomes data from the JUPITER trial, the rela-
tive risk reduction of rosuvastatin 20 mg compared with no treatment was carried 
forward beyond the trial period. Baseline CVD event risk was age adjusted using 
Framingham equation. Cost- effectiveness was assessed from a payer perspective using 
direct medical costs and a lifetime horizon. Life tables and CVD-attributable mortality 
risk estimates were derived from Mexican national statistics data. Results are presented 
in U.S. dollars (exchange rate 13 MXN/dollar). RESULTS: The model was run for a 
hypothetical cohort of 100,000 patients at higher risk of CVD events (men 61%, age 
67 years, mean Framingham risk 15%). Estimated quality adjusted life years (QALYs) 
gained with rosuvastatin therapy compared with no treatment was 31,723 over lifetime 
and 23,946 over a 20-year horizon. Over lifetime, 11,680 events were avoided: 6,076 
non-fatal MIs, 2,596 non-fatal strokes, and 3,729 CVD deaths. The estimated incre-
mental cost-effectiveness ratio (ICER) for cost per QALY was $8,91 for a lifetime 
horizon. For a hypothetical cohort similar to the overall JUPITER population, the ICER 
was $11,764/QALY over lifetime. For a 20-year horizon, similar ICERs were estimated 
for the higher-risk ($11,327/QALY) and JUPITER patient populations ($16,279/
QALY). CONCLUSIONS: In a higher-risk Mexican population with the mean Fram-
ingham risk of 15%, treatment with rosuvastatin 20 mg daily is a cost-effective treat-
ment alternative if the willingness to pay per QALY is higher than $8291.
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OBJECTIVES: To assess cost-effectiveness of rosuvastatin 20 mg treatment in second-
ary prevention of major cardiovascular disease (CVD) events and mortality for 
patients with a previous CVD event. METHODS: A probabilistic Monte Carlo simula-
tion model estimated long-term cost-effectiveness of rosuvastatin therapy (20 mg 
daily) for prevention of CVD mortality and morbidity in patients with a previous CVD 
event (60% men, age 61 years, mean Framingham score 25%). The relative risk 
reduction observed with rosuvastatin 20 mg in the JUPITER (Justiﬁcation for the Use 
of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial 
was used in this secondary-prevention setting based on available literature indicating 
similar efﬁcacy of statins in primary- and secondary-prevention settings. The quarterly 
event probabilities were used to construct survival curves for patients in both the 
treatment and placebo groups. The relative risk of rosuvastatin was estimated and 
extrapolated beyond the trial duration. The event rates were age adjusted beyond the 
trial duration. The difference in baseline risk between the JUPITER trial population 
and population of interest was adjusted using Framingham score. A payer perspective 
was assessed with direct medical costs and up to a lifetime horizon. RESULTS: For a 
hypothetical cohort of 100,000 patients with a previous history of CVD and 25% 
Framingham risk score, estimated quality-adjusted life-years (QALYS) gained with 
rosuvastatin therapy compared with placebo was 54,319 over lifetime, and 39,252 
and 15,341 over 20-year and 10-year horizons, respectively. Rosuvastatin 20 mg 
avoided 14,373 events over lifetime (8,327 non-fatal MIs, 3,218 non-fatal strokes, 
and 4,292 CVD deaths avoided). Rosuvastatin 20 mg dominated (more effective and 
less costly) over lifetime and 20-year time horizon. The incremental cost-effectiveness 
ratio for cost per QALY over 10 years was $18,549. CONCLUSIONS: Results indi-
cate rosuvastatin 20 mg to be cost-effective in secondary-prevention treatment of 
patients with a history of CVD events.
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OBJECTIVES: To evaluate the costs, beneﬁts, and incremental cost-effectiveness of 
non-invasive imaging of cardiac sympathetic innervation using AdreView in patients 
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with chronic left ventricular dysfunction at increased risk for sudden cardiac death as 
compared to current risk stratiﬁcation methods for selection of patients for implanted 
cardiac deﬁbrillators (ICD) versus medical therapy. METHODS: A Markov model 
was developed to evaluate the impact of using AdreView for evaluating NYHA II or 
III heart failure (HF) patients with LV ejection fraction (EF) <50% for treatment with 
an ICD. AdreView risk-stratiﬁcation was used to guide the treatment decision between 
ICD and medical therapy. The source of data for predicted probabilities, expected 
mortality rates, and treatment costs in year 2009 dollars are from the published litera-
ture and the AdreView Myocardial Imaging for Risk Evaluation in Heart Failure 
(ADMIRE-HF) study. The model was developed from a societal perspective using a 
one-month cycle time, 3% discount rate and a lifetime time horizon. Sensitivity analy-
sis was completed on cost, efﬁcacy and relative risk ratios. RESULTS: AdreView had 
an incremental cost-effectiveness ratio (ICER) of $100,910 versus standard stratiﬁca-
tion methods. The number needed to screen to prevent one death over 5 years was 
20. The model was sensitive to changes in utility values ($91,737–$112,123 / QALY), 
efﬁcacy of ICD in low risk patients ($95,805–$107,388 / QALY) and efﬁcacy of ICD 
in high risk patients ($81,578–$166,086 / QALY). The model was not sensitive 
AdreView cost, even at 200% of baseline ($104,068 / QALY). CONCLUSIONS: 
AdreView is a relatively cost-effective screening strategy versus current methods that 
can prevent sudden cardiac deaths within as few as 20 patient screenings. Further 
research on the use of AdreView in real-world settings is warranted.
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OBJECTIVES: Compare the cost-effectiveness of rosuvastatin versus standard man-
agement according to Framingham risk for the primary prevention of vascular events 
in JUPITER-like patients that had LDL levels less than 130 mg/dL and CRP levels of 
2.0 mg/L or higher. METHODS: TreeAge Pro 2009 software was used to design 2 
Markov-type models from a third party payer perspective to calculate the incremental 
cost-effectiveness ratio (ICER) of rosuvastatin 20 mg versus standard management 
over 10 years in patients with a Framingham Risk Score greater than 10% and less 
than or equal to 10%. Cost data were obtained from CMS and the Redbook. Quality 
of life measures were obtained from the literature. Event data were obtained directly 
from the JUPITER Study Group. One-way sensitivity analysis and probabilistic sen-
sitivity analysis were conducted on many possible ranges of cost, quality of life 
measures, and event rates. RESULTS: Treating patients with rosuvastatin to prevent 
vascular events would result in an estimated ICER of $37,232/QALY and $95,000/
QALY in those with Framingham Risk Scores greater than 10%, and less than or 
equal to 10%, respectively. Results of 1-way sensitivity analysis were especially sensi-
tive to the price of the rosuvastatin and the probability of a primary endpoint event 
in the standard management group. Results of a probabilistic sensitivity analysis 
suggest that in patients with a Framingham score greater than 10%, the probability 
that rosuvastatin would be considered cost-effective at a $50,000/QALY threshold is 
approximately 97.5%. In those patients with a Framingham Risk Score less than or 
equal to 10%, the probability that rosuvastatin would be considered cost-effective is 
less than 1%. CONCLUSIONS: Compared with standard management practices, 
statin therapy with rosuvastatin may be a cost-effective strategy over a 10-year time 
horizon for preventing vascular events in patients with a Framingham Risk Score 
greater than 10% that have normal LDL levels and elevated CRP levels.
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OBJECTIVES: In Turkey, there is Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin 
and Simvastatin in the statin market. And all statins are reimbursed by health insur-
ance companies.The aim of this study is to determine the cost-effective statins which 
are reimbursted by the Social Security Foundation,the biggest reimburestment founda-
tion in Turkey. METHODS: A cost-effectiveness analysis was designed from the 
perspective of the insurance company view. For insurance company data; Social 
Security Foundation which is the biggest reinburstment foundation in Turkey was 
chosen. The assumed treatment protocol depended on the one in the Republic of 
Turkey Health Ministery Primary Care Diagnosis and Treatment Guide which was 
published in 2003.The values of the mean effectiveness of statins are taken from a 
published meta-analysis. RESULTS: Simvastatin had the lowest cost in the ﬁrst year 
of therapy ($166), followed by pravastatin ($300),ﬂuvastatin ($365),rosuvas-
tatin($437) and atorvastatin($448). When the drugs were compared for the incremen-
tal cost-effectiveness, simvastatin dominated pravastatin and ﬂuvastatin,whereas 
rosuvastatin dominated atorvastatin.The ﬁrst year incremental cost of rosuvastatin 
was $271 compared to simvastatin, or $30 per additional 1% reduction in LDL-C, 
$225 per additional 1% increase in HDL-C and $1856 per additional patients to ATP 
II goal. CONCLUSIONS: Because simvastatin had a lower acquisition cost than all 
statins and its all dosages cost approximately 1/3 of the nearest alternative statin, in 
our base case and alternative scenarios simvastatin was the least costly alternative. 
Thus depending on actual acquisition prices and following costs such as doctor visits 
and laboratories the payer may achieve substantial cost savings and greater effective-
ness by using rosuvastatin or simvastatin instead of these agents in Turkey. Therefore, 
simvastatin and rosuvastatin comprise of the optimal two statin formulary. Formulary 
desicion based on these results should be revisited periodically, as new pricing, out-
comes and safety data become available.
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OBJECTIVES: To evaluate the cost-effectiveness of treating patients without tradi-
tional risk factors for cardiovascular disease with statins. METHODS: Cost-effective-
ness was evaluated using a backward induction model. A hypothetical cohort of men 
and women aged 40 to 80 years was evaluated for their ﬁrst acute myocardial infarction 
(AMI) or cardiovascular accident (CVA). The Reynolds Risk Score (RRS) was used to 
generate event risks and risk reductions as the impact of therapy on lipids and c-reactive 
protein (CRP) could be calculated independently. Covariates for the RRS were adapted 
from the JUPITER trial and national health statistics. Life expectancies, quality of life 
adjustments, and event costs for AMI and CVA were ascertained from the primary 
literature. Direct and indirect treatment costs were based on the primary literature, 
Adult Treatment Panel III (ATPII) protocols and the Bureau of Labor Statistics. Medi-
cation costs were adapted from the Federal Supply Schedule. Costs were inﬂated to 
2009 US$ using the medical component of the CPI and discounted at a rate of 3%. A 
sensitivity analysis was also performed. RESULTS: Using a threshold of $150,000 per 
QALY, treatment was cost-effective with generic statins in all men and women, aged 
40 to 80 years when both CRP and LDL levels were affected. It was cost-effective to 
treat men >60 years with a hypothetical medication that only affected CRP levels. In 
the base case (65 year old men/women), the model was sensitive to adherence, smoking 
status (women), premature family history of AMI, brand rosuvastatin price, and the 
level of LDL reduction. CONCLUSIONS: In this population, it is cost-effective to treat 
all patients for the primary prevention of AMI and CVA with a generic statin that 
confers therapeutic beneﬁts similar to what was modeled in this study. Selectively 
lowering CRP levels is only cost-effective in males >60 years.
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OBJECTIVES: A decision-analytic model using cost data and clinical information 
from the PREVAIL study showed that enoxaparin was cost-saving from the payer 
perspective compared with unfractionated heparin (UFH) for the prevention of venous 
thromboembolism (VTE) in patients with acute ischemic stroke (overall costs of clini-
cal events plus drug costs: $2018 vs. $2913, respectively; difference $895 per patient). 
To test the robustness of the cost difference of enoxaparin versus UFH for VTE 
prevention after an acute ischemic stroke, univariate and multivariate sensitivity 
analyses were performed. METHODS: In the univariate analysis, the payer cost 
(2007$) for each clinical event (deep-vein thrombosis [DVT], pulmonary embolism 
[PE]; intracranial hemorrhage [ICH], major extracranial hemorrhage [MjEH] and 
minor extracranial hemorrhage [MnEH]) was adjusted individually, increasing or 
decreasing by 20%, while other parameters (drug costs, event rates) remained 
unchanged. The multivariate analysis was a Monte Carlo simulation (Crystal Ball 
software), where all the parameters were simultaneously varied in a random fashion 
within a range of ± 20% over 10,000 trials. RESULTS: The cost of DVT was $13,499. 
When increased by 20% to $16,199, the difference between UFH and enoxaparin 
groups was $1,104; when decreased by 20% to $10,799, the difference was $686. 
The baseline costs were $20,635 for PE, $26,037 for ICH, $22,765 for MjEH and 
$815 for MnEH. When these were increased by 20%, the difference between enoxa-
parin and UFH groups was $928, $907, $859 and $896, respectively. When decreased 
by 20%, the difference was $862, $883, $932 and $894. Using the Monte Carlo 
simulation multivariate analysis, the difference varied between $615 and $1,177, with 
mean (SD) $896 ($91) and median of $897. Enoxaparin was less costly than UFH 
across all analyses, with DVT being the main cost driver. CONCLUSIONS: Univariate 
and multivariate sensitivity analysis conﬁrmed that enoxaparin is more cost-saving 
than UFH for VTE prevention after an acute ischemic stroke.
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OBJECTIVES: To identify, retrieve, and summarize studies evaluating the cost-effec-
tiveness of selected cardiac imaging tests for the diagnosis of CAD. METHODS: 
